(1-((6-Chloropyridin-3-yl)methyl)piperidin-3-yl)methanol dihydrochloride

Catalog No. :
ACMEFR013
CAS No. :
1185312-32-6
Molecular Formula :
C12H19Cl3N2O
Molecular Weight :
313.66

IUPAC Name:(1-((6-chloropyridin-3-yl)methyl)piperidin-3-yl)methanol dihydrochloride

(1-((6-Chloropyridin-3-yl)methyl)piperidin-3-yl)methanol dihydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$450.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(1-((6-Chloropyridin-3-yl)methyl)piperidin-3-yl)methanol dihydrochloride
IUPAC Name(1-((6-chloropyridin-3-yl)methyl)piperidin-3-yl)methanol dihydrochloride
MDL No.MFCD09607574
Molecular FormulaC12H19Cl3N2O
Molecular Weight313.66
SMILESOCC1CN(CC2=CC=C(Cl)N=C2)CCC1.[H]Cl.[H]Cl
InChI KeyVUATULOCBLCAEG-UHFFFAOYSA-N
Synonym[1-(6-Chloro-pyridin-3-ylMethyl)-piperidin-3-yl]-Methanol dihydrochloride, 98+% C12H19Cl3N2O, MW: 313.65;1-[(6-Chloro-3-pyridinyl)methyl]-3-piperidinemethanol hydrochloride
CAS No.1185312-32-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACMEFR013 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCTJM471 route compound structure diagram
    ACCTJM47123100-12-1 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMEFR013 route product structure diagram
    ACMEFR0131185312-32-6
Inquiry

2. ACMEFR013 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMEFR013 route product structure diagram
    ACMEFR0131185312-32-6
Inquiry

Comments (0)